Genmab

GMAB.CO

Tags: DK Healthcare Biotechnology

Genmab A/S Price (GMAB.CO)

Stock Price

Low: Year Low

High: Year High

Market Cap

Fetching Data...

Enterprise Value

Fetching Data...

Shares Outstanding

64,632,940

(1.9446)%

Market Cap of Genmab (GMAB.CO)

Market cap:

As of , GMAB.CO has a market cap of . This makes GMAB.CO the 4th most valuable company in the DK by market cap. Market capitalization, or market cap, is the total value of a company's outstanding shares of stock, calculated by multiplying the current stock price by the total number of shares.

Year

Beginning Of Year

End Of Year

YOY Change

Revenue and Profitability

Year	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Revenue	0	68,326,000	4,101,000	98,505,000	135,547,000	529,537,000	745,113,000	586,076,000	582,077,000	350,936,000	484,636,000	663,570,000	850,385,000	1,133,041,000	1,816,122,000	2,365,436,000	3,025,137,000	5,366,000,000	10,111,000,000	8,482,000,000	14,595,000,000	16,474,000,000	21,526,000,000
Net Income	478,677,000	327,246,000	372,692,000	-429,277,000	-473,247,000	-438,282,000	-965,089,000	-347,898,000	-143,317,000	-215,748,000	-111,448,000	70,155,000	301,296,000	763,513,000	1,187,075,000	1,103,551,000	1,472,141,000	2,166,000,000	4,758,000,000	2,957,000,000	5,452,000,000	4,352,000,000	7,844,000,000
FCF USD	-409,137,000	-317,066,000	-375,964,000	-211,078,000	-381,562,000	493,056,000	-566,349,000	-586,839,000	258,061,000	-444,430,000	61,921,000	-138,364,000	57,229,000	176,060,000	294,610,000	1,500,462,000	537,420,000	1,215,000,000	6,126,000,000	1,976,000,000	3,595,000,000	7,004,000,000	7,584,000,000
OCF USD	-308,316,000	-302,364,000	-367,698,000	-208,644,000	-379,623,000	505,898,000	-513,333,000	-570,061,000	268,171,000	-437,225,000	70,919,000	-127,999,000	132,671,000	311,449,000	327,719,000	1,588,972,000	1,014,786,000	1,326,000,000	6,433,000,000	2,228,000,000	3,912,000,000	7,380,000,000	7,771,000,000

Financial Health - DEBT

Year	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
YTPD	0.00	-0.06	-0.05	-0.04	-0.03	-0.02	-0.01	-0.02	-0.04	-0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.05	0.09	0.07	0.12	0.12
D/E	0.01	0.02	0.02	0.02	0.01	0.01	0.01	0.02	0.12	0.02	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.02	0.02	0.02	0.02	0.03
CA/CL	8.84	14.21	17.04	5.58	9.53	3.67	1.85	2.41	1.83	1.55	1.40	1.87	4.22	8.85	11.90	18.52	16.77	14.88	15.00	14.50	15.57	13.34	5.25
TA/TL	8.61	12.60	13.99	5.45	9.16	3.68	3.04	2.40	1.77	1.45	1.29	1.62	3.44	9.39	12.73	19.96	18.94	13.82	10.46	10.13	10.67	9.59	5.03
Total Debt	13,775,000	24,137,000	29,004,000	23,036,000	18,206,000	15,667,000	14,699,000	24,942,000	133,717,000	11,845,000	5,660,000	2,485,000	355,000	118,000	0	0	0	181,000,000	319,000,000	425,000,000	597,000,000	770,000,000	1,029,000,000

Management Performance

Year	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
ROIC	43.61%	-30.82%	32.73%	-40.88%	-31.37%	-17.24%	-29.47%	-60.61%	-14.71%	-43.21%	-22.22%	12.71%	12.15%	21.10%	22.91%	22.22%	15.72%	14.04%	25.52%	9.86%	17.49%	12.49%	14.13%
ROE	34.21%	30.12%	31.56%	-38.37%	-29.44%	-15.20%	-44.10%	-26.82%	-13.27%	-44.35%	-29.08%	10.64%	14.82%	21.90%	24.59%	17.59%	18.37%	15.42%	24.88%	13.32%	19.87%	13.77%	21.38%
ROA	0.00%	-27.72%	-32.64%	-28.72%	-24.28%	-9.68%	-29.60%	-45.50%	-12.11%	-37.74%	-28.93%	6.22%	10.37%	19.41%	21.58%	16.11%	19.05%	18.88%	27.92%	16.17%	23.23%	15.97%	17.12%
NM %	-	478.95%	9,087.83%	-435.79%	-349.14%	-82.77%	-129.52%	-59.36%	-24.62%	-61.48%	-23.00%	10.57%	35.43%	67.39%	65.36%	46.65%	48.66%	40.37%	47.06%	34.86%	37.36%	26.42%	36.44%
FCF / R%	0.00%	-464.05%	-9,167.62%	-214.28%	-281.50%	93.11%	-76.01%	-100.13%	44.33%	-126.64%	12.78%	-20.85%	6.73%	15.54%	16.22%	63.43%	17.77%	22.64%	60.59%	23.30%	24.63%	42.52%	35.23%
FCF / NI%	85.36%	96.93%	90.55%	53.63%	87.07%	-128.61%	58.72%	58.06%	-85.86%	75.27%	-12.64%	-128.55%	19.25%	23.24%	26.07%	141.06%	33.34%	42.50%	103.76%	49.61%	51.10%	124.25%	96.69%
Operating Margin (OM)	-	-15.07	-352.26	-18.76	-16.33	-4.73	-4.45	-7.12	-7.61	-14.27	-11.31	-8.07	-5.91	-3.73	-1.71	-0.78	-0.07	0.40	0.70	1.18	1.03	1.15	1.09

Per Share

Year	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
EPS	21.43	14.33	14.08	-13.73	-12.16	-9.97	-21.62	-7.75	-3.19	-4.80	-2.42	1.38	5.35	13.05	19.83	18.14	24.03	34.40	73.00	45.22	83.38	66.64	122.21
SPS	0.00	2.99	0.15	3.15	3.48	12.05	16.69	13.05	12.96	7.81	10.53	13.02	15.10	19.36	30.33	38.88	49.38	85.22	155.13	129.70	223.21	252.24	335.37
OCPS	-13.80	-13.24	-13.89	-6.68	-9.75	11.51	-11.50	-12.70	5.97	-9.74	1.54	-2.51	2.36	5.32	5.47	26.12	16.56	21.06	98.70	34.07	59.83	113.00	121.07
FCPS	-18.32	-13.89	-14.20	-6.75	-9.80	11.22	-12.69	-13.07	5.75	-9.90	1.34	-2.71	1.02	3.01	4.92	24.66	8.77	19.30	93.99	30.22	54.98	107.24	118.16
BVPS	62.64	47.59	44.62	35.79	41.30	65.61	49.02	28.89	24.05	10.83	8.32	12.94	36.10	59.58	80.61	103.10	130.81	223.12	293.36	339.41	419.67	484.00	571.72

Per Share - CAGR

Year	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
CAGR-EPS	21.43	14.33	14.08	-13.73	-12.16	-9.97	-21.62	-7.75	-3.19	-4.80	-2.42	1.38	5.35	13.05	19.83	18.14	24.03	34.40	73.00	45.22	83.38	66.64	122.21
CAGR-SPS	0.00	2.99	0.15	3.15	3.48	12.05	16.69	13.05	12.96	7.81	10.53	13.02	15.10	19.36	30.33	38.88	49.38	85.22	155.13	129.70	223.21	252.24	335.37
CAGR-OCPS	-13.80	-13.24	-13.89	-6.68	-9.75	11.51	-11.50	-12.70	5.97	-9.74	1.54	-2.51	2.36	5.32	5.47	26.12	16.56	21.06	98.70	34.07	59.83	113.00	121.07
CAGR-FCPS	-18.32	-13.89	-14.20	-6.75	-9.80	11.22	-12.69	-13.07	5.75	-9.90	1.34	-2.71	1.02	3.01	4.92	24.66	8.77	19.30	93.99	30.22	54.98	107.24	118.16
CAGR-BVPS	62.64	47.59	44.62	35.79	41.30	65.61	49.02	28.89	24.05	10.83	8.32	12.94	36.10	59.58	80.61	103.10	130.81	223.12	293.36	339.41	419.67	484.00	571.72

Revenue $21.53B

+30.67%

10Y

Net Income $7.84B

+80.24%

10Y

Operating Cash Flow $7.77B

+5.30%

10Y

Free Cash Flow $7.58B

+8.28%

10Y

YTPD $0.12

-0.98%

10Y

D/E $0.03

+15.11%

10Y

CA/CL $5.25

-60.67%

10Y

TA/TL $5.03

-47.60%

10Y

ROIC $14.13%

+13.17%

10Y

ROE $21.38%

+55.25%

10Y

ROA $17.12%

+7.19%

10Y

Net Margin $36.44%

+37.94%

10Y

FCF / R% $35.23%

-17.13%

10Y

FCFNI % $96.69%

-22.19%

10Y

Operating Margin $1.09

-5.25%

10Y

EPS $122.21

+83.39%

10Y

SPS $335.37

+32.95%

10Y

OCPS $121.07

+7.14%

10Y

FCPS $118.16

+10.18%

10Y

BVPS $571.72

+18.12%

10Y

Wordpress Tutorials

eCommerce Website Tutorials

Responsive Design

Genmab

Stock Price

Fetching Data...

Fetching Data...

Fetching Data...

64,632,940

Market Cap of Genmab (GMAB.CO)

Market cap:

Year

Beginning Of Year

End Of Year

YOY Change

Revenue of Genmab (GMAB.CO)

Revenue:

Year

Revenue

YOY Change

Net Income of Genmab (GMAB.CO)

Net Income:

Year

Net Income

YOY Change

Free Cash Flow of Genmab (GMAB.CO)

Free Cash Flow:

Year

FreeCash flow

YOY Change

Operating Cash Flow of Genmab (GMAB.CO)

Operating Cash Flow:

Year

Operating Cashflow

YOY Change

Return on Invested capital of Genmab (GMAB.CO)

Return on Invested capital: %

%

Year

Return on Invested Capital

YOY Change

Return on Equity of Genmab (GMAB.CO)

Return on Equity: %

%

Year

Return on Equity

YOY Change

Return on Assets of Genmab (GMAB.CO)

Return on Assets: %

%

Year

ROA

YOY Change

Total debt of Genmab (GMAB.CO)

Total debt:

Year

MarketCap

YOY Change

Marketing Budget of Genmab (GMAB.CO)

Marketing Budget:

Year

MarketCap

YOY Change

Employee of Genmab (GMAB.CO)

Employee:

Year

Employees Number

YOY Change

Payroll of Genmab (GMAB.CO)

Payroll:

Year

Payroll

YOY Change

Dividends of Genmab (GMAB.CO)

Dividends:

Year

Dividends

YOY Change

Executive Compensation of Genmab (GMAB.CO)

Executive Compensation: